CAS 160969 00 6 Silodosin Intermediates 2- 2- 2 2 2-trifluoroethoxy phenoxy ethyl bromide cGMP

CAS No . : 160969-00-6 Silodosin Intermediate 2 - ( 2 - ( 2 , 2 , 2  - trifluoroethoxy ) phenoxy ) ethyl bromide

Chemical Name : 2 - ( 2 - ( 2  ,2 , 2 - trifluoroethoxy ) phenoxy ) ethyl bromide 

CAS No . : 160969-00-6

Short Code : SL-1

Molecular Formula : C10H10BrF3O2

Molecular Weight : 299.08

Usage : Silodosin Intermediate 

Description :

Silodosin is an active pharmaceutical ingredient ( API ) used for the symptomatic treatment of benign prostatic hyperplasia - BPH acting as alpha1-adrenoceptor antagonist with high selectivity of prostate. It does not shrink the prostate but relax the muscles in the prostate and bladder.

It is first approved in Japan in May 2006 under the brand name Urief, which is jointly marketed by Daiichi Sankyo Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd. The US, Canada and Mexico rights were lincensed to Watson Pharmaceutical Co., Ltd by Kissei Pharmaceutical in 2004 and Silodosin was approved by FDA in Oct 9, 2008. Silodosin has many trade names, Rapaflo in USA, Silodyx in Europe and South Africa, Rapilif, Silodal or Sildoo in India, Urief in Japan, Thrupas in South Korea, Urorec in Russia and so on.

2 - ( 2 - ( 2 ,2 , 2 - trifluoroethoxy ) phenoxy ) ethyl bromide CAS No . : 160969-00-6 is an intermediate for the synthesis of Silodosin. Some patents might be still valid in some countries and regions. We promise to supply the real route of synthesis to the buyers. But anyway the buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.